Conolidine’s analgesic effects stem from its conversation with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors in the central anxious program, conolidine modulates alternate molecular targets. A Science Advances analyze located that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://mitchj146omi7.wikissl.com/user